What is Semax nasal spray?
Semax nasal spray is the standard clinical form of Semax administration. The preparation consists of a peptide dissolved in a sterile aqueous solution and administered as drops or a fine mist directly into the nasal cavity. This is the form in which Semax has been used in Russian clinical practice since its registration in Russia in the 1990s, for the treatment of ischaemic stroke, cerebrovascular insufficiency, and optic nerve diseases. It is also the method of administration used in the majority of published clinical trials on humans.
The nasal spray formulation was specifically chosen because it allows the peptide to travel directly from the nasal cavity to the brain via the olfactory pathway – the network of nerves responsible for the sense of smell. This direct route bypasses the need to cross the blood-brain barrier through the bloodstream and avoids gastrointestinal degradation, which would destroy the peptide if swallowed.
It should be emphasised that Semax nasal spray and Semax for injection contain precisely the same active molecule. The difference lies solely in the method of peptide delivery to the body and the effectiveness of reaching the brain – which has significant implications for dosage, duration of action, and the profile of effects. The nasal route favours brain effects due to direct access to the brain, whereas injection routes deliver the peptide to the general bloodstream first, causing wider distribution to both the brain and peripheral tissues.
How does Semax nasal spray reach the brain?
Semax nasal spray reaches the brain via the olfactory pathway—a direct anatomical shortcut from the nasal cavity to brain tissue that completely bypasses the blood-brain barrier. Once the spray is administered and the liquid contacts the upper nasal mucosa—the moist inner lining of the nasal cavity—the olfactory epithelium absorbs the peptide. The olfactory epithelium is specialized tissue within the upper nasal cavity that contains the nerve endings responsible for the sense of smell. From there, Semax travels along the olfactory nerve fibres directly to the olfactory bulb—the brain's first smell-processing centre—and then onward to deeper brain structures.
Pharmacokinetic studies using a radioactively labelled version of Semax confirmed that approximately 0.093% of the administered dose per gram of brain tissue was detectable as early as 2 minutes after intranasal administration. Approximately 80% of this early brain radioactivity represented intact Semax, rather than its metabolic products [1]. This exceptionally rapid access to the brain — measurable concentrations in the brain within just 2 minutes — demonstrates that the nasocerebral route is very rapid and effective for this peptide.
The olfactory pathway is not the only route by which intranasally administered Semax reaches the brain. Some absorption also occurs through the nasal mucosa into the general bloodstream, from which the peptide can cross the blood-brain barrier via systemic circulation – although this indirect route is slower and delivers lower concentrations to the brain. The trigeminal nerve pathway – another neural network running directly from the nasal cavity to the brainstem – offers a third direct route. The combination of these pathways means that intranasal Semax achieves significant concentrations in brain tissue, which would be difficult to obtain through systemic injection without much higher doses. This is why the intranasal route produces stronger cognitive effects per dose than intraperitoneal or subcutaneous injection [2].
How effective is Semax nasal spray?
Semax nasal spray is effective in inducing cognitive, neuroprotective, and neurobiological effects documented in published studies. In clinical stroke studies, nasal Semax at daily doses of 12–18 milligrams accelerated neurological recovery, improved motor functions, and raised plasma BDNF levels in human patients [3], [4]. In patients with optic nerve diseases, Semax administered to the nasal mucosa improved visual acuity, expanded the visual field, and enhanced the electrical sensitivity and conductivity of the optic nerve [5].
In healthy volunteers, intranasal Semax induced measurable changes in the default mode network during resting-state fMRI already 5 minutes after administration [6]. This confirms the rapid and significant engagement of the brain after intranasal administration.
Animal studies consistently show strong effects after intranasal administration, including increased hippocampal BDNF [7], behavioural changes reducing anxiety and resembling antidepressant effects [8], and improvements in learning and memory tasks [2].
What is the difference between 0.1% and 1% Semax nasal spray?
The difference between 0.1% and 1% Semax nasal spray is a tenfold difference in peptide concentration — one is ten times stronger than the other — which directly determines the amount of Semax delivered per drop or spray. The 0.1% solution contains 1 milligram of Semax per millilitre of liquid. The 1% solution contains 10 milligrams of Semax per millilitre. This difference in concentration has direct practical implications for dosing precision and determines the clinical or research applications for which each concentration is suitable. Both concentrations have been used in published studies and in Russian clinical practice.
In Russian clinical practice, a concentration of 1% — 10 milligrams per millilitre — is the standard formulation used in the treatment of ischaemic stroke, where relatively high daily doses of 12–18 milligrams are required [3]. A concentration of 0.1% — 1 milligram per millilitre — is used in contexts requiring lower doses, for example in the treatment of optic nerve disorders [5] and in applications where more precise control of lower doses is desired.
How many micrograms per drop does Semax nasal spray deliver?
The amount of Semax delivered per drop depends on two factors: the concentration of the solution and the volume of each drop. Standard pharmaceutical nose drops deliver about 50 microlitres per drop—microlitres being thousandths of a millilitre—though this can vary slightly depending on the design of the dropper bottle.
Using this standard drop volume as a reference: a 0.1% solution delivers approximately 50 micrograms per drop, whilst an 1% solution delivers approximately 500 micrograms per drop.
These calculations provide approximate values based on standard drop volumes. In a pharmacokinetic study investigating the intranasal administration of Semax, a dose of 50 micrograms per kilogram of body weight in rats was administered in a volume of 20 microlitres [1].
It is important that the conversion of rat doses to equivalent human doses requires complex pharmacokinetic adjustments, which cannot be done by simple body weight multiplication. No published study has formally established equivalent human doses through pharmacokinetic bridging studies.
What concentration should be used?
The appropriate concentration is entirely dependent on the intended dose and the volume that can be comfortably administered into the nasal cavity. A practical limitation is that the total volume delivered intranasally should remain small. Large volumes are uncomfortable, tend to drip down into the throat rather than being absorbed by the nasal mucosa, and are less effectively absorbed via the olfactory pathway. Maintaining a total intranasal volume of approximately 100–200 microlitres—roughly 2–4 drops per nostril—represents a practical upper limit for comfortable and effective intranasal absorption. This means that higher doses necessitate higher concentrations to deliver the desired amount of peptide within an absorbable volume.
It should be emphasised that the above information is for pharmacological and practical purposes and is not a recommendation for self-administration of Semax. The appropriate concentration for individual use in a clinical context is a decision for a qualified healthcare professional. Semax is not approved for self-administration in most countries.
How is Semax nasal spray administered?
In published clinical trials and Russian clinical practice, Semax nasal spray is administered as drops applied directly to the nasal mucosa. The patient is typically positioned with their head tilted back slightly so that the drops contact the upper nasal epithelium – a specialised tissue in the upper part of the nasal cavity where the olfactory nerve endings are most concentrated.
The correct anatomical target is the olfactory region in the upper nasal cavity – not the inferior nasal passages where most nasal sprays are directed – because it is this upper area that contains the olfactory epithelium through which direct nose-to-brain transport occurs.
In clinical trials, daily doses were divided into several administrations throughout the day. In an efficacy study in stroke patients, daily doses of 12 milligrams for moderate strokes and 18 milligrams for severe strokes were administered in two courses of 10 days each, with a 20-day break between courses [3]. In a clinical study of optic nerve diseases, Semax was administered either as nasal drops or via intranasal electrophoresis—a technique that uses a mild electrical current to introduce the solution deeper into the nasal mucosa—with the electrophoresis group showing the most pronounced and longest-lasting improvements [5].
How long does Semax nasal spray take to be absorbed?
Semax achieves measurable concentrations in the brain within 2 minutes of intranasal administration, according to a pharmacokinetic study with radioactive labelling [1]. This makes it one of the fastest-absorbing administration methods for any neuroactive compound.
The subjective onset of cognitive effects reported by users typically corresponds with this rapid pharmacokinetic profile, with changes in mental clarity and alertness often reported within 15–30 minutes. At the gene expression level, measurable changes in BDNF and NGF mRNA were detectable in rat brain tissue as early as the earliest measured time point—20 minutes after a single intranasal dose [9]. This confirms that the biological cascade triggered by Semax entry into the brain begins very rapidly after administration.
Can you prepare Semax nasal spray yourself?
Reconstituting lyophilised peptide powder – that is, freeze-dried (frozen and vacuum-dried) peptide powder – into a solution for intranasal administration is technically achievable, but requires careful attention to sterility, accurate measurements, and appropriate preparation conditions. The process involves dissolving a precisely weighed amount of peptide powder into a measured volume of sterile bacteriostatic water – sterile aqueous solution containing a small amount of a preservative called benzyl alcohol – or sterile saline solution to achieve the target concentration. The solution is then transferred into a sterile spray bottle or dropper.
Critical safety requirements are significant. Pharmaceutical-grade sterile water is required. Precise weighing equipment is necessary for measuring peptide powder on a milligram scale, as concentration errors can lead to dosing inaccuracies. A completely sterile preparation environment is essential to prevent bacterial or fungal contamination. Appropriate storage conditions are needed to maintain the stability and sterility of the solution.
Contamination of nasal preparations with bacteria, fungi, or endotoxins – toxic by-products of bacterial breakdown – can lead to serious local or systemic infections. No published studies have validated protocols for the home preparation of nasal Semax spray, and this practice carries inherent risks that professional pharmaceutical manufacturing is specifically designed to eliminate.
Can Semax be injected?
Yes, Semax can be administered via subcutaneous injection – that is, injection into the fatty layer directly under the skin – and this route has been used in some animal studies and is discussed in nootropic communities. However, it is not a standard clinical method of administration in published human studies.
Most published studies of Semax in humans have used nasal administration, which provides enhanced delivery to the central nervous system via the direct olfactory pathway. Subcutaneous injection delivers the peptide to the fatty tissue directly beneath the skin, from where it is absorbed into the bloodstream and distributed throughout the body, reaching the brain by crossing the blood-brain barrier via systemic circulation. This systemic delivery route induces a different profile of effects than nasal administration—involving broader distribution to peripheral tissues, slower brain penetration, and evidence suggesting more pronounced analgesic effects. However, it may elicit relatively weaker cognitive enhancement effects per unit dose [2].
A direct comparative study showed that intraperitoneal administration – injection into the abdominal cavity, a route used exclusively in studies with similar distribution to subcutaneous injection – evoked analgesic effects absent with intranasal administration. Intranasal administration, in turn, evoked a stronger improvement in learning than the systemic route [2]. This route-dependent difference in effects is important for understanding why the two administration methods are not simply interchangeable in terms of expected outcomes.
How to prepare Semax for injection?
Preparation of Semax for subcutaneous injection from lyophilised powder requires reconstitution in sterile bacteriostatic water. Bacteriostatic water – containing a small amount of benzyl alcohol as a preservative – is preferred over plain sterile water for multi-dose vials, as the preservative inhibits bacterial growth between uses.
The process involves drawing an appropriate volume of bacteriostatic water into a syringe, and then slowly injecting it along the wall of the vial containing the lyophilised powder. The water should not be directed straight onto the powder cake – the compressed dry mass of the peptide – as this can damage the peptide's structure. The vial is then gently swirled – not shaken vigorously, which can also damage the peptide – until the powder completely dissolves into a clear solution.
The safety requirements for preparing an injection are significantly more demanding than for a nasal preparation. Strict aseptic technique – a sterile, contaminant-free preparation process – is essential to prevent injection site infections or systemic sepsis, a life-threatening whole-body infection. Accurate concentration calculation is necessary to avoid dosing errors. The reconstituted solution should be visually inspected for particulate matter or cloudiness prior to use, as either would indicate potential contamination or degradation. Proper disposal of used needles and syringes into a sharps container is also required.
These requirements are not trivial. Injection carries risks of infection, vascular injury, and nerve damage, which nasal administration does not.
Where to inject Semax?
The subcutaneous injection sites for Semax are consistent with standard conventions for other subcutaneously administered peptides and for insulin injections. The most commonly used sites are the abdomen at least 2 centimetres from the navel, the outer thigh, or the back of the upper arm. The abdomen is generally preferred due to the ease of self-administration and consistent absorption.
The injection should be administered into the subcutaneous tissue layer – the fatty tissue directly beneath the skin – rather than into the muscle (intramuscular injection) or a blood vessel (intravenous injection), as these are different techniques with different safety profiles. Standard technique involves pinching a fold of skin to lift the subcutaneous tissue away from the muscle below, inserting the needle at a 45-degree angle for thin individuals or a 90-degree angle if there is sufficient subcutaneous tissue, injecting slowly, and then withdrawing the needle while releasing the skin fold.
Injection sites should be rotated with each administration to prevent local tissue irritation or lipohypertrophy, which is the hardening and thickening of fatty tissue that can develop at a repeatedly used injection site.
What equipment is needed for Semax injection?
Standard subcutaneous injection requires insulin syringes – typically with very thin 29–31 gauge needles and a capacity of 0.5–1 millilitre suitable for small peptide doses. Bacteriostatic water is needed to reconstitute lyophilised powder. Alcohol swabs are used to disinfect the rubber stopper of the vial and the skin at the injection site prior to administration. A sharps container – a puncture-resistant container specifically designed for the safe disposal of needles – is required for the safe disposal of used needles and syringes.
Insulin syringes are particularly suitable for subcutaneous injection of peptides as their very fine needles minimise discomfort and tissue trauma. Their small volume capacity also corresponds to the low volumes typically required for concentrated peptide solutions.
What dosages were used in the studies?
To begin, it must be clearly stated that no published clinical trials have established a validated dosing regimen for subcutaneous injection of Semax in humans for any indication. Dosing information available from published studies comes primarily from animal studies using intraperitoneal administration and from Russian clinical practice using intranasal administration. The translation of animal or intranasal clinical doses to subcutaneous human doses cannot be performed with scientific precision using currently published data.
In animal studies, intraperitoneal doses ranging from 0.015 to 0.6 milligrams per kilogram of body weight were used to investigate cognitive, anxiolytic, and neuroprotective effects [2], [8], [10]. In Russian clinical practice, intranasal doses of 12–18 milligrams per day were used for ischaemic stroke in divided administrations [3].
The Semax dose-response relationship in humans – that is, the relationship between the size of the dose and the magnitude of the evoked effect – has not been formally characterised. This means that the dosage range that elicits optimal effects versus the range that elicits adverse effects remains entirely undetermined for this population and route of administration.
Discussions within nootropic communities typically refer to subcutaneous doses ranging from 200–600 micrograms per injection. This represents user-derived practices extrapolated from animal and clinical nasal dosage studies, rather than validated pharmacokinetic or pharmacodynamic data in humans. This context must be clearly understood by anyone evaluating such information.
How often would Semax be injected in research protocols?
In animal studies using intraperitoneal administration, Semax was typically given once daily [10, 11], which aligns with the 20–24-hour duration of action reported in early human studies with nasal administration [12].
Russian clinical courses for intranasal Semax typically lasted 10 days, sometimes repeated after a break, rather than involving indefinite continuous daily use. This cyclical approach – administering a compound for a set duration and then taking a break – aligns with Semax's neurotrophic mechanism, which works by inducing changes in gene expression and stimulating the brain's own production of growth factors. These are mechanisms that do not require constant receptor stimulation to elicit lasting neuroplastic changes.
It cannot be determined from published data whether subcutaneous injection in humans would follow a similar daily or cyclical schedule.
Can Semax and Selank be injected together?
Semax and Selank are chemically compatible peptides that could theoretically be mixed in the same syringe for simultaneous administration. Both are water-soluble heptapeptides with no known chemical incompatibilities between them. Encephalinase inhibition studies demonstrated that both peptides interact with the same enzymatic systems in human serum without significant interference with each other's activity [13], providing indirect evidence of biochemical compatibility.
However, no published studies have formally investigated the pharmacokinetics, stability, or pharmacodynamic interactions of Semax and Selank when mixed in the same solution. Whether one peptide degrades the other under storage or administration conditions – and whether mixing them alters how each behaves – remains unknown.
In Russian clinical practice, both peptides are administered intranasally as separate preparations, rather than as a ready-made mixed preparation. The practical approach used in research settings is to administer each peptide separately – either at different times or via separate administrations – in order to maintain independent control over the dosage of each compound.
What do studies say about the combined effects of Semax and Selank?
The most significant published data regarding the effects of combining Semax and Selank comes from a resting-state functional MRI brain connectivity study that analysed both peptides in the same group of 52 healthy participants – although each participant received only one compound per session, not the combination [14]. The study revealed that Selank and Semax induced both shared and unique effects on functional connectivity between the right amygdala and temporal cortical areas. Post-hoc analysis identified both general effects common to both peptides and specific effects for each [14]. The shared effects suggest common pharmacological ground, while the unique effects confirm that each peptide contributes distinct pharmacological actions – providing a scientific rationale for why their combination may induce a broader profile of effects than either alone.
Both peptides inhibit the enzymes that break down enkephalins in human serum. Semax does this with an IC50 of 10 micromoles, and Selank with an IC50 of 20 micromoles [13]. A combination would therefore lead to an expectation of greater total inhibition of these enzymes than each peptide alone. The pentapeptide fragments produced when each peptide is degraded in the body also showed independent inhibitory activity, suggesting that the breakdown products of both peptides together would interact with overlapping enzyme and receptor systems in a complex, yet potentially additive, manner [13].
Nasal spray vs injection for Semax and Selank
The choice between intranasal administration and subcutaneous injection of Semax and Selank involves significant trade-offs in terms of target tissue concentrations, onset characteristics, and practical convenience.
Intranasal administration provides better direct delivery to the brain via the olfactory pathway — demonstrated by rapid 2-minute brain penetration documented for Semax [1] — and elicits stronger cognitive effects per dose compared with systemic routes [2]. The intranasal route is also the only clinically validated human administration route with published safety and efficacy data from controlled trials.
Subcutaneous injection bypasses the olfactory pathway and delivers both peptides first to the general circulation, prompting wider distribution to peripheral tissues alongside central brain effects. For Semax, this systemic distribution signifies greater engagement of receptors outside the brain – including peripheral melanocortin and opioid receptors – potentially eliciting more pronounced effects on pain sensitivity and peripheral immune modulation [2], [15]. For Selank, which shows documented immunomodulatory effects and cytokine regulation significant in peripheral tissues [16], systemic delivery may be particularly relevant for these non-central nervous system actions.
From a practical point of view, intranasal administration is considerably simpler. It does not require injection equipment or sterile preparation techniques, carries no risk of needle-stick infection, and elicits rapid cognitive effects noticeable within minutes. Subcutaneous injection introduces complexity, infection risk, and practical barriers without a clearly established benefit for the purposes of cognitive enhancement based on available evidence.
For anyone operating outside a supervised medical context, the nasal route offers a more favourable overall risk-benefit profile based on published literature.
Disclaimer
This article is for educational and scientific informational purposes only and should not be interpreted as medical advice, diagnosis, therapy recommendation, or an instruction for self-administration of any compound. Semax and Selank remain research compounds in most countries, including the United States and most European countries, and are not approved by the Food and Drug Administration (FDA) or the European Medicines Agency (EMA) for the treatment of any medical condition. They are approved and used clinically in Russia and some Eastern European countries. The information regarding administration presented here reflects clinical and research practices documented in the published literature and is not intended to guide or encourage self-administration. Most of the evidence comes from preclinical animal studies and a limited number of human clinical trials. Additional well-designed clinical trials are necessary to more accurately establish safety, efficacy, appropriate dosing, and long-term effects in humans.
References
Shevchenko, K. V., Nagaev, I. Yu., Alfeeva, L. Yu., Andreeva, L. A., Kamenskii, A. A., Levitskaia, N. G., Shevchenko, V. P., Grivennikov, I. A., & Miasoedov, N. F. (2006). Kinetics of Semax penetration into the brain and blood of rats after its intranasal administration. Bioorganic Chemistry, 32 (1), 64–70. https://doi.org/10.1134/s1068162006010055
[2] Manchenko, D. M., Glazova, N. Yu., Levitskaia, N. G., Andreeva, L. A., Kamenskiĭ, A. A., & Miasoedov, N. F. (2010). Nootropic and analgesic effects of Semax following different routes of administration. Rossiyskiy Fiziologicheskiy Zhurnal imeni IM Sechenova, 96 (10), 1014–1023. PMID: 21268834 https://pubmed.ncbi.nlm.nih.gov/21268834/
[3] Gusev, E. I., Skvortsova, V. I., Miasoedov, N. F., Nezavibat’ko, V. N., Zhuravleva, E. Yu., & Vanichkin, A. V. (1997). Effectiveness of semax in the acute period of hemispheric ischaemic stroke. Journal of Neurology and Psychiatry named after SS Korsakov, 97 (6), 26–34. PMID: 11517472 https://pubmed.ncbi.nlm.nih.gov/11517472/
[4] Gusev, E. I., Martynov, M. Yu., Kostenko, E. V., Petrova, L. V., & Bobyreva, S. N. (2018). The efficacy of semax in the treatment of patients at different stages of ischaemic stroke. Journal of Neurology and Psychiatry n.a. SS Korsakov, 118 (3), 61–68. https://doi.org/10.17116/jnevro20181183261-68
Polunin, G. S., Nurieva, S. M., Baiandin, D. L., Sheremet, N. L., & Andreeva, L. A. (2000). Evaluation of therapeutic effect of new Russian drug semax in optical nerve disease. Journal of Ophthalmology, 116 (1), 15–18. PMID: 10741256
[6] Lebedeva, I.S., Panikratova, Ya. R., Sokolov, O. Yu., Kupriyanov, D. A., Rumshiskaya, A. D., Kost, N. V., & Myasoedov, N. F. (2018). Effects of Semax on the default mode network of the brain. Bulletin of Experimental Biology and Medicine, 165 (5), 653–656. https://doi.org/10.1007/s10517-018-4234-3
[7] Dolotov, O.V., Karpenko, E.A., Seredenina, T.S., Inozemtseva, L.S., Levitskaya, N.G., Zolotarev, Yu. A., Kamensky, A. A., Grivennikov, I. A., Engele, J., & Myasoedov, N. F. (2006). Semax, an analogue of adrenocorticotropin (4-10), binds specifically and increases levels of brain-derived neurotrophic factor protein in rat basal forebrain. Journal of Neurochemistry, 97 (Suppl 1), 82–86. https://doi.org/10.1111/j.1471-4159.2006.03658.x
[8] Inozemtseva, L. S., Yatsenko, K. A., Glazova, N. Yu., Kamensky, A. A., Myasoedov, N. F., Levitskaya, N. G., Grivennikov, I. A., & Dolotov, O. V. (2024). Antidepressant-like and antistress effects of the ACTH(4-10) synthetic analogues Semax and Melanotan II on male rats in a model of chronic unpredictable stress. European Journal of Pharmacology, 984 , 177068. https://doi.org/10.1016/j.ejphar.2024.177068
[9] Shadrina, M., Kolomin, T., Agapova, T., Agniullin, Y., Shram, S., Slominsky, P., Lymborska, S., & Myasoedov, N. (2010). Comparison of the temporary dynamics of NGF and BDNF gene expression in rat hippocampus, frontal cortex, and retina under Semax action. Journal of Molecular Neuroscience, 41 (1), 30–35. https://doi.org/10.1007/s12031-009-9270-z
[10] Levitskaya, N. G., Sebentsova, E. A., Andreeva, L. A., Alfeeva, L. Yu., Kamenskii, A. A., & Myasoedov, N. F. (2004). The neuroprotective effects of Semax in conditions of MPTP-induced lesions of the brain dopaminergic system. Neuroscience and Behavioural Physiology, 34 (4), 399–405. https://doi.org/10.1023/b:neab.0000018752.59465.28
[11] Volodina, M. A., Sebentsova, E. A., Glazova, N. Yu., Manchenko, D. M., Inozemtseva, L. S., Dolotov, O. V., Andreeva, L. A., Levitskaya, N. G., Kamensky, A. A., & Myasoedov, N. F. (2012). Correction of long-lasting negative effects of neonatal isolation in white rats using semax. Acta Naturae, 4 (1), 86–92. PMID: 22708068
[12] Ashmarin, I. P., Nezavibat’ko, V. N., Miasoedov, N. F., Kamenskiĭ, A. A., Grivennikov, I. A., Ponomareva-Stepnaia, M. A., Andreeva, L. A., Kaplan, A. Ia., Koshelev, V. B., & Riasina, T. V. (1997). A nootropic adrenocorticotropin analogue 4-10-Semax (15 years' experience in its design and study). Journal of Higher Nervous Activity named after I.P. Pavlov, 47 (2), 420–430. PMID: 9173745
[13] Kost, N. V., Sokolov, O. Yu., Gabaeva, M. V., Grivennikov, I. A., Andreeva, L. A., Miasoedov, N. F., & Zozulia, A. A. (2001). Semax and selank inhibit the enkephalin-degrading enzymes from human serum. Organic Chemistry, 27 (3), 180–183. https://doi.org/10.1023/a:1011373002885
[14] Panikratova, Ya. R., Lebedeva, I. S., Sokolov, O. Yu., Rumshiskaya, A. D., Kupriyanov, D. A., Kost, N. V., & Myasoedov, N. F. (2020). Functional connectomic approach to studying Selank and Semax effects. Doklady Biological Sciences, 490 (1), 9–11. https://doi.org/10.1134/S001249662001007X
[15] Liu, R., Chen, Y., Huang, H., Li, X., Lv, J., Jiang, L., Jiang, H., Wu, C., Chen, W., Xu, H., Zhu, Z., Cai, H., Xiao, J., Yin, L., & Ni, W. (2025). Semax peptide targets the μ opioid receptor gene Oprm1 to promote deubiquitination and functional recovery after spinal cord injury in female mice. British Journal of Pharmacology, 182 (22), 5489–5516. https://doi.org/10.1111/bph.70122
[16] Yasenyavskaya, A. L., Samotrueva, M. A., Tsibizova, A. A., Bashkina, O. A., Myasoedov, N. F., & Andreeva, L. A. (2021). The influence of Selank on the level of cytokines under the conditions of „social” stress. Current Reviews in Clinical and Experimental Pharmacology, 16 (2), 162-167. https://doi.org/10.2174/1574884715666200704152810